PubMed
LL-37, the only human member of the cathelicidin family of antimicrobial peptides
Vandamme D, Landuyt B, Luyten W, et al. Biochim Biophys Acta. 2012
Compare
LL-37 vs Wolverine Blend
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
LL-37
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 100–400 mcg
100–200
4
200–400
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Wolverine Blend
965 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 59% · Mixed 28% · Unfavorable overall 13%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
-24
Mood
7
Focus
-57
Sleep quality
3
Lean mass
-57
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Dizziness
-108
Fatigue
-93
Nausea
-92
Water retention
-1
Appetite loss
-58
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.025–2 mg
0.025–0.05 mg
3
0.05–0.1 mg
14
0.1–0.2 mg
23
0.2–0.4 mg
31
0.4–0.6 mg
25
0.6–1 mg
14
1–2 mg
9
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing49stacking22side effects25wolverine blend23
How repeat users are trending
Among repeat reporters, 54% said they felt similar to their last entry, 33% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 19 days · Based on 212 repeat reporters
Sources (7)
Published sources linked on the LL-37 and Wolverine Blend wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
The antimicrobial peptide LL-37 inhibits biofilm formation
Dean SN, Bishop BM, van Hoek ML. BMC Microbiol. 2011
- Wiki study page →Source
ClinicalTrials.gov
LL-37 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Rosacea: Pathogenesis and Therapeutic Correlates
Geng RSQ, Bourkas AN, Mufti A, et al. Journal of cutaneous medicine and surgery. 2024
- Wiki study page →Source
PubMed
LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review
Soman D, P J, Cm M, et al. Archives of oral biology. 2026
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
- Wiki study page →Source
PubMed
Thymosin beta 4 and wound healing: a multifunctional peptide
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010